China's Drug Out-Licensing Passed $120 Billion. The BD Talent Didn't Scale With It. | Henderson Headhunter

Three Deals in Four Days, and a Rewritten Playbook

The fortnight around the start of October set the tone. On 2 October, Abogen, a Suzhou-based biotech founded in 2019, announced a licensing and option agreement with Novartis giving the Swiss group worldwide rights to ABO2203, an mRNA-encoded CD19xCD3 T-cell engager, for $575 million upfront and up to roughly $7.2 billion in milestones, plus options on other programmes built on Abogen's RNA platform. What changed hands was not a single asset but a capability that keeps producing assets. On 29 September, Novo Nordisk licensed HRS-1596, an oral once-weekly GLP-1/GIP dual agonist from Hengrui, for rights outside Greater China at $300 million upfront and up to $2.6 billion in milestones. On 1 October, Sanofi and Regeneron expanded a two-decade-old antibody partnership with four long-acting candidates, a $1 billion upfront and up to $7 billion in milestones, Regeneron leading development and Sanofi global commercialisation.

The pattern runs deeper than the headlines. In August, Haisco licensed a preclinical autoimmune asset to Sentivera for about $75.9 million upfront and up to $1.46 billion in milestones, and Gan & Lee licensed a GLP-1 candidate to Menarini across 39 European countries. The flow is spreading from the largest listed groups into second-tier developers, where recruitment pressure is most acute: these companies rarely have an in-house deal team, and almost never have a global clinical organisation.

From Selling Seedlings to Co-Development

To see why the talent gap opened, it helps to understand how the model changed. For most of the past decade, Chinese biotech out-licensing followed one route: sell the overseas rights outright, early, for an upfront that funded the next few years of domestic R&D. Chinese companies called it selling seedlings — the seedling was gone, and the tree grew in someone else's garden, with global development, late-stage clinical work and commercial upside belonging to the buyer. The logic was sound when Chinese developers had neither the capital nor the overseas clinical and commercial machinery to run a global programme themselves.

The terms have started to reverse. Across this year's large transactions, co-development, co-commercialisation and post-launch profit sharing appear far more often. Five of the twenty programmes Innovent runs with partners including Pfizer use a co-development and co-commercialisation structure, and Hengrui's partnership with Bristol Myers Squibb includes five programmes developed jointly, with Hengrui able to take part in global commercialisation. The centre of gravity of the economics is moving from upfronts and clinical milestones to profit sharing after launch — a concession multinationals historically did not make. Two forces explain it: on the buy side, a wave of patent expiries has left pipelines short and external sourcing urgent; on the sell side, Chinese assets have improved, and the first half's approvals included a cluster of first-in-class mechanisms.

The balance sheets support the shift. Industry data show 362 listed biopharma companies reporting combined first-half revenue of 889.9 billion yuan and operating profit of 113.7 billion yuan, up 11.17% year on year. BeiGene passed 22.2 billion yuan in first-half revenue, Innovent reported 8.62 billion yuan, up 44.76%, with net profit exceeding the whole of 2025, and several peers turned profitable on large upfronts. Cash from licensing is what lets a company build an overseas organisation — and the people that organisation needs sit in the scarcest tier of the market.

The BD and Licensing Bench

Business development used to sit quietly inside a strategy or corporate affairs function, a handful of people with limited influence. When deals move from a few a year to one nearly every week, and upfronts move from tens of millions to hundreds of millions of dollars, the job changes weight. How a molecule is valued, how the upfront splits against milestones, how territory is carved, how post-launch profit is divided — those clauses can decide a company's revenue for a year. The people who negotiate them have become the most expensive line in the organisation.

The profile is scarce because it stacks three capabilities: scientific judgement (reading a mechanism, weighing preclinical data, pricing an asset), deal structure (upfronts, milestones, royalties, co-development), and cross-border negotiation across language, culture and legal systems. Few people hold all three, and China has no established training path for the role — most practitioners came from clinical, R&D or strategy. Henderson Executive Search's recruitment specialists see the constraint at the supply end. The people who have run a full nine-figure licensing deal sit in a small number of large Chinese groups and multinational China affiliates; they are employed, well paid, and reachable mainly through direct approach. Salary research reports put BD director-level pay above one million yuan a year, with heads who lead cross-border licensing commanding considerably more, this cycle's increases outpacing R&D roles. A retained search for the role typically runs four to six months, front-loaded into mapping and approach.

Which Modality Is Fighting for Which Team

Value in out-licensing is concentrated in a few modalities, and recruitment demand concentrates with it. Bispecifics and antibody-drug conjugates carry the largest totals: 3SBio licensed a PD-1/VEGF bispecific to Pfizer at $1.25 billion upfront; Akeso licensed a PD-1/LAG-3 bispecific to Sanofi at $550 million; Hengrui licensed a TROP2 ADC to Merck at $850 million; RemeGen licensed a Claudin18.2 ADC to AstraZeneca at $720 million, with Phase III data read out. With more than 120 bispecific programmes in development in China, the order flow is unlikely to slow. The scarce roles sit in antibody engineering, conjugation and translational medicine — profiles that both read a molecule and drive process scale-up.

Small nucleic acids are this year's variable. Three large deals in the first half alone passed $7.1 billion in total value, more than the whole of 2025, led by Ribo's siRNA licence to Madrigal at $4.4 billion total. The unlock is extrahepatic delivery: where the field once concentrated on liver targets, delivery now reaches kidney, cardiovascular and even central nervous system tissue, filling a gap for multinational buyers. Delivery and CMC talent is being fought over accordingly, from a pool that sits in a handful of nucleic-acid companies. Metabolic disease is the steadier long game, with the global GLP-1 market above $200 billion and growing roughly 25% a year — the logic behind Novo's oral dual agonist deal with Hengrui — and peptide synthesis and oral formulation specialists moving up the list.

From Licensing to Capability Building

As the model shifts, demand moves from the transaction to the delivery behind it. The first requirement is global clinical development. When a programme is co-developed, the Chinese side joins the design, running and readout of multi-region trials, which calls for people fluent in FDA and EMA dialogue and global clinical operations. That bench sat historically inside multinational global teams, and domestic companies are still building theirs. The second is regulatory strategy. Drug registration is a different discipline from device registration, testing command of national drug regulations and accelerated pathways, plus coordination with a partner's regulatory team; when the strategy is set governs how soon a programme can launch overseas.

The third is cross-border intellectual property and legal capability. An out-licensing deal is an asset transaction whose subject is a patent estate and a clinical dataset: due diligence before signing, licence scope and exclusivity terms during negotiation, and patent maintenance and infringement risk afterwards. Chinese lawyers and licensing counsel with a life-science background remain thin, concentrated in a few top firms and multinational legal departments. Henderson Executive Search's senior consultants note that on co-development deals, legal and IP are among the first support functions pulled into the project team, and as deal volume rises the role is moving from secondment toward a permanent seat.

The Second Curve in Emerging Markets

With partnerships in the US and Europe maturing, South America, the Middle East and Southeast Asia are entering the frame. Analysis from a securities research house argues these regions are relatively under-supplied and offer Chinese developers room to serve local markets in more accessible forms. Gan & Lee's grant of European rights to Menarini is instructive: it kept its domestic rights while borrowing a partner's local specialisation and pharmacy channels. Talent demand in these regions differs from the West — local channel access, understanding of reimbursement systems and in-country registration matter more than fluency with multinational deal teams.

Fosun Pharma's president has put the same point another way: overseas commercialisation turns on culture, compliance and payment systems, so the early phase works best as a companion-style partnership with local players. That is the shape of the hiring problem. In the West, companies need BD and global clinical talent who can face a multinational counterpart; in emerging markets, they need operators who understand a local market and can run registration and channels. The two profiles do not overlap. Two timing points are worth planning for. A licensing negotiation typically runs three to six months, while a BD head who can lead a cross-border deal takes four to six months to place — start after the data readout and the window may close. And once co-development enters the terms, clinical and regulatory people must be in place around signing, because their arrival sets the pace of the programme. Henderson Executive Search runs biopharma and innovative-drug searches from Guangzhou, covering the biotech clusters of the Greater Bay Area and the Yangtze River Delta, and sequencing talent ahead of the deal is consistently cheaper than backfilling after it.

FAQ

Q: Which roles are hardest to fill in Chinese biotech out-licensing right now?

A: Three clusters. BD and licensing leadership that combines scientific judgement, deal structuring and cross-border negotiation; global clinical development talent, because co-development requires the Chinese side to help run multi-region trials; and cross-border IP and licensing counsel, since an out-licensing deal is an asset transaction in patents and data. Regulatory strategy follows closely, though drug registration does not transfer from medical devices.

Q: Why is a BD head so hard to hire?

A: The role stacks three capabilities, and China has no established training path for it — most practitioners moved over from clinical, R&D or strategy. People who have completed a nine-figure cross-border licensing deal sit in a small number of large groups and multinational China affiliates; they are employed and well paid. Henderson Executive Search finds the difficulty lies not in applicant volume but in reaching them directly.

Q: How does co-development change the hiring plan?

A: Under an outright sale, the overseas programme passes to the buyer and the Chinese side needs few people. Once co-development and co-commercialisation enter the terms, global clinical, regulatory strategy and medical affairs move from optional to required — and must be in place around signing. That is a direct reason out-licensing-related recruitment has risen this year.

Q: Where do companies find global clinical and regulatory talent for drug development?

A: Two main sources: clinical operations and regulatory staff from multinational China affiliates or global teams who have run multi-region trials, and teams at leading domestic developers already running trials abroad. The first bring process discipline but need to adapt to domestic decision speed; the second ramp faster and know Chinese pipelines. Drug and device registration differ enough that the two talent pools are not interchangeable.

Q: How should a company choose a life-science headhunter for out-licensing roles in China?

A: Three tests. Has the firm completed searches in the same modality and the same role family — BD, global clinical, regulatory, IP — and does it understand where the boundaries lie? Can it map where the target candidates sit rather than forward a résumé stack? Will it stay engaged three months after the start date? Henderson Executive Search runs biopharma and innovative-drug searches from Guangzhou, inside the Greater Bay Area's biotech cluster.